A Texas-based transitional dialysis program decreased emergency department visits and hospital admissions by providing outpatient dialysis access to uninsured patients. The program, piloted in Travis County, resulted in most patients obtaining permanent dialysis access within a year.
A global study found stable AKI-related mortality rates globally, but with differing patterns indicating a rise in mortality among older adults and high-income countries. The study also revealed declining mortality rates in low- and middle-income countries due to improvements in healthcare access.
A quality improvement intervention implemented at a Thai hospital resulted in a significant reduction of metformin-associated lactic acidosis (MALA) deaths. The protocol included immediate dialysis and increased awareness, reducing mortality rates by 13.9% and care variation.
A prediction model estimates individualized survival probabilities with conservative non-dialytic management versus dialysis transition in patients with advanced chronic kidney disease. The study found certain factors, including older age and higher albuminuria levels, linked to higher mortality risk.
A new study suggests that including a patient's 2-year risk of progression to kidney failure as a decision-making tool can improve patient outcomes and reduce racial disparities in kidney transplantation. The study found that this approach prioritizes individualized care and could benefit younger patients with chronic kidney disease.
High-impact clinical trials are generating promising results for improving kidney health, according to recent studies. These trials are paving the way for innovative treatments and therapies to combat kidney diseases.
A recent analysis of the SPRINT trial suggests that nearly all adults with CKD would experience benefits outweighing the harms from a systolic blood pressure target <120 mm Hg. The study found greater net benefits for more advanced CKD groups, supporting KDIGO guidelines.
Researchers found that dual SGLT1/2 inhibition reduces mean arterial pressure and attenuates kidney injury more effectively than selective SGLT2 inhibition. Sotagliflozin also improves urinary sodium, chloride excretion, and fractional glucose excretion.
New research reveals that primary glomerular diseases in children and young adults may experience faster kidney function decline than older patients. Pediatric patients with biopsy-diagnosis of MCD had steeper eGFR declines compared with adult patients.
Recent clinical trials have demonstrated significant benefits in kidney health, including improved patient outcomes and reduced disease progression. These findings have the potential to revolutionize treatment approaches for patients with kidney disease.
High-impact clinical trials have generated promising results for improving kidney health, according to a recent study. The findings suggest that these trials may lead to better treatment options and improved patient outcomes.
New phase 3 clinical trials show potential for improving kidney health outcomes with targeted therapies, such as pegcetacoplan and semaglutide. These studies have the potential to revolutionize kidney care and treatment.
Researchers have developed a novel gene therapy called PS-002, which targets podocytes and blocks complement activation to treat IgA nephropathy. In mouse models, treatment with PS-002 reduced signs of kidney dysfunction and lowered complement deposition, while in pigs, it resulted in elevated gene expression without safety issues.
A Phase 3 trial of clazakizumab, a monoclonal antibody targeting interleukin-6, failed to demonstrate efficacy in treating chronic active antibody-mediated kidney transplant rejection. The study, which recruited 350 patients, showed no significant improvement in kidney function at week 52.
A phase 2 clinical trial found imlifidase to be more effective than plasmapheresis in reducing donor-specific antibodies by 97% compared to 42%. The investigational drug achieved maximum DSA depletion in 15 hours, outperforming the standard treatment.
A recent study found that GLP-1RA medications are not associated with an increased risk of acute kidney injury (AKI) in patients receiving anti-cancer therapies. Researchers analyzed medical records of 14,783 patients and discovered a lower incidence of AKI among those taking GLP-1RA compared to those without exposure.
Recent phase 3 clinical trials have generated promising results for improving kidney health, including finerenone and semaglutide's effects on kidney parameters. These findings will be presented at ASN Kidney Week 2024.
A novel approach combines 17 biomarkers to identify three distinct health dimensions: systemic inflammation and filtration, tubular function, and tubular damage. Higher tubular damage scores were associated with higher risk of CKD progression, while lower tubular function scores predicted mortality risk.
A recent analysis of clinical trial data reveals that SGLT2 inhibitor canagliflozin reduces major adverse cardiovascular events, hospitalization for heart failure or cardiovascular death, and chronic kidney disease progression in older adults. The effects on safety outcomes are not modified by age.
Chronic kidney disease (CKD) prevalence and mortality rates have increased significantly among women worldwide, with a 2.10% annual percentage change in prevalence and a 3.39% increase in mortality. The study highlights the need for policy interventions and public awareness campaigns to curb the rise of CKD.
Felzartamab induces rapid and durable depletion of galactose-deficient IgA1 and total IgA antibodies in patients with IgA nephropathy. The treatment maintains Gd-IgA1 reduction for up to 9 months off-treatment, offering a potential breakthrough in managing this autoimmune kidney disease.
Researchers analyzed over 16,000 biopsies from nearly 7,000 kidney transplant recipients to uncover key insights into microvascular inflammation. The study found reclassified patients with microvascular inflammation in the absence of antibody-mediated responses displayed an increased risk of graft failure.
A real-world analysis of 3,450 kidney transplant patients treated with SGLT2 inhibitors found significant reductions in kidney transplant rejection (59% less likely), kidney transplant failure (33% less likely), major adverse cardiac events (40% less likely), and mortality risk (44% less likely) over a 3-year period.
A new analysis found that county-level structural racism is a significant determinant of death among individuals with kidney failure. Black patients experienced survival advantages at lower levels of structural racism but disadvantages at higher levels.
Researchers found a positive association between elevated urinary albumin and sub-clinical coronary artery pathology, including microcalcifications, in individuals with type 2 diabetes without symptoms of cardiovascular disease. Microcalcification activity was higher in those with albuminuria, indicating potential kidney damage.
Researchers have created a comprehensive atlas of human fetal kidney development, revealing transitions between different cell states. The study identifies key genes associated with rare genetic diseases and offers insights into the heritability of adult kidney traits.
Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been shown to reduce the risk of sustained decline in estimated glomerular filtration rate and cardiorenal composites by 38% and 23%, respectively. The findings support previously reported benefits of sotagliflozin in reducing cardiovascular events.
Researchers analyzed 43 clinical trials and found that trial participants were less diverse than actual transplant recipients in the US. The study suggests that efforts are needed to improve participant diversity in clinical trials to better reflect real-world patients.
Results from high-impact clinical trials will be presented at ASN Kidney Week 2023, offering potential improvements in kidney-related medical care. The trials bring together leading experts and professionals to exchange knowledge and discuss the latest advances.
A study found that exposure to wildfire smoke and fine particulate matter increased the risk of hospitalization and death among hemodialysis patients by 3% and 5%, respectively. Wildfires pose a significant health risk for vulnerable populations, including those with kidney failure.
A new study investigated the safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes who also have cancer. The research revealed a higher risk of diabetic ketoacidosis and fracture, but lower risks of acute kidney injury and urinary tract infection compared to another diabetes medication called GLP-1 RA.
Researchers found that vancomycin treatment reduced inflammation in the kidney and increased beneficial bacteria, while polymyxin B showed no significant effect. The study suggests modifying gut microbiota through antibiotic administration may help alleviate hypertensive organ damage.
Researchers have implemented an automated health maintenance tool to prompt primary care physicians to screen for chronic kidney disease in adult patients with type 2 diabetes. The tool has shown higher rates of testing for kidney function screening tests after implementation.
A study found that combining medications can substantially prolong patients' survival free of kidney failure. For a 50-year-old patient, estimated survival was 17.0 years with combination therapy versus 9.6 years with no treatment.
A recent study examines the environmental sustainability practices of dialysis facilities in Australia and New Zealand, revealing multiple areas for improvement. The survey-based study identified opportunities to reduce waste and resource consumption, with only 33% of facilities responding to the survey indicating a lack of prioritizat...
A study published in CJASN found that symptoms related to kidney failure worsened before dialysis but stabilized after initiation. The analysis revealed a significant decrease in symptom number and burden after dialysis, particularly for fatigue and sexual symptoms.
Researchers developed a strategy combining urinary albumin:creatinine ratio (UACR) and glomerular filtration rate (GFR) slope to predict treatment effects on patient outcomes. This approach improved predictions in phase 2 clinical trials with sample sizes of 100–200 patients per arm or follow-up times ranging between 1 and 2 years.
The COVID-19 pandemic has significantly increased the mortality risk of hemodialysis patients, with risks persisting at higher levels for those with confirmed infections. Other patients on dialysis experienced slightly elevated mortality risk during peak pandemic periods.
A recent analysis of COVID-19 cases in four waves found that individuals with chronic kidney disease were more likely to develop severe forms of COVID-19 and experience complications. Pre-existing conditions, including CKD, were consistent clinical predictors of COVID-19 severity across multiple pandemic waves.
Patients with advanced kidney disease may benefit from conservative non-dialytic management over dialysis for hospitalization prevention. Patients of Asian ethnicity show the highest hospitalization rates on early dialysis compared to late dialysis or conservative management. Conservative management underutilized in US due to uncertain...
Research analyzed 350,994 participants and found that higher air pollution concentrations increased the risk of developing chronic kidney disease. Individuals with high air pollution exposure and low genetic risk faced a significantly higher risk of developing CKD compared to those with high genetic risk.
The American Society of Nephrology presents results from high-impact clinical trials that could transform kidney-related medical care. The trials will focus on improving patient outcomes and advancing the treatment of kidney diseases.
Researchers have created a polygenic risk score for pediatric steroid-sensitive nephrotic syndrome, which is associated with earlier age of onset in children. The score was generated from genetic data and showed promise in predicting the development of the condition.
Researchers developed an AI-based algorithm to predict major adverse kidney events within 90 days of discharge. The algorithm accurately predicted 19.7% of patients' development of acute kidney injury or chronic disease.
A population-level study found that COVID-19 vaccine doses 2-3 were associated with a higher relative risk but small absolute increase in glomerular disease relapse. Most flares were mild, and the benefits of vaccination outweighed the risks.
An AI-based model has been developed to predict patients' risk of acute kidney injury (AKI), which is common in intensive care units. The model was validated in four medical centers and showed accuracy in predicting AKI 24 hours ahead of time.
A study published in the American Society of Nephrology found that one-third of patients with chronic kidney disease experienced worsening symptoms over time, leading to a higher risk of needing dialysis and death. The study identified two profiles of symptom trajectories: those with worsening symptoms and those with stable symptoms.
A recent study examined public comments from Canadians regarding deemed consent legislation, which automatically assumes consent for deceased organ donation. The study found that while some people supported the legislation, others raised concerns about individual autonomy and potential errors. The authors emphasize the importance of pu...
A recent study in the Netherlands provides an estimate of the proportion of working-aged kidney transplant recipients who are employed and identifies characteristics associated with lower work functioning. Despite side effects of immunosuppressive therapy and fatigue, stable kidney transplant recipients often function well at work.
A new study finds that using race-free equations for estimating kidney function can minimize racial differences in accrued preemptive waiting time. The research suggests that a specific equation, creatinine-based, reduces racial disparities more effectively than another equation, cystatin C-based.